Common Stock, $0.001 par value
- Symbol
- SBEV
- Exchange
- NYSEAMER
- Classification
- COMMON
- Status
- Historical · closed Jun 4, 2026
Current Report · Items 1.01, 7.01, 9.01 · 8-K
Endovia Health Sciences, Inc.
EDVANYSE_AMERICANEQUITYCurrent
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Item 1.01 Entry into a Material Definitive Agreement On July 28, 2026, Splash Beverage Group, Inc. (the “Company”) and Argent BioPharma Limited (ASX/LSE: RGT) (the “Licensor”) entered into an addendum (the “Addendum”) to that certain exclusive global license agreement for CannEpil®, dated July 6, 2026 (the “License Agreement”). Pursuant to the Addendum, the License Agreement was amended to:…
Company context
The Company is a Nevada corporation that was historically seeking to identify, acquire, and build early stage or under-valued beverage brands that have strong growth potential within its distribution system. During the current fiscal year beginning January 1, 2026, the Company has moved away from beverages and is focusing on the cannabinoid and health and wellness economy businesses.
Current securities
Registered securities in this filing
SPLASH BEVERAGE GROUP, INC. · 8-K · Filed 2026-07-29
Disclosure sections
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement
On July 28, 2026, Splash Beverage Group, Inc. (the
“Company”) and Argent BioPharma Limited (ASX/LSE: RGT) (the “Licensor”) entered into an addendum (the “Addendum”)
to that certain exclusive global license agreement for CannEpil®, dated July 6, 2026 (the “License Agreement”). Pursuant
to the Addendum, the License Agreement was amended to: (i) expand the field of use under the License Agreement to include veterinary applications;
(ii) provide for an amended royalty rate payable to the Licensor equal to 10% of Net Revenue (as defined in the License Agreement) attributable
to veterinary applications and 15% of Net Revenue attributable to human applications; and (iii) extend various deadlines provided for
under the License Agreement. The Company previously disclosed the License Agreement and filed a copy thereof as Exhibit 10.1 in the Company’s
Current Report on Form 8-K filed on July 6, 2026.
The foregoing description of the Addendum does not
purport to be complete and is qualified in its entirety by reference to the full text of the Addendum, a copy of which is filed as Exhibit
10.1 and is incorporated herein by reference.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On July 29, 2026, Splash Beverage Group, Inc. issued
a press release announcing that it has expanded its exclusive global license for CannEpil® with Argent BioPharma Limited (ASX/LSE:
RGT) to include veterinary applications. A copy of the press release is furnished as Exhibit 99.1 of this Current Report on Form 8-K.
The information in this Item 7.01 (including Exhibit
99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)
or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of
the Company under the Securities Act of 1933 or the Exchange Act.
Filed exhibits (1)
EX-99.1 3 e7811_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 Splash Beverage Group Expands CannEpil® Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program Expansion broadens CannEpil into veterinary therapeutics as Splash advances its cannabinoid pharmaceutical development platform FORT LAUDERDALE, Fla., July 29, 2026 - Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”) today announced that it has expanded its exclusive global license for CannEpil® to include veterinary therapeutic applications, creating a second regulated pharmaceutical development platform alongside the Company’s existing human pharmaceutical program. The expanded field of use grants Splash exclusive worldwide rights to develop, manufacture, commercialize, market and distribute CannEpil for veterinary diseases and conditions. CannEpil is a proprietary pharmaceutical-grade cannabinoid formulation consisting of cannabidiol (CBD) and tetrahydrocannabinol (THC) isolates formulated in an oral liquid solution and manufactured under European Union Good Manufacturing Practice (EU-GMP) standards. Originally developed as a potential treatmen…
Open exhibit ↗